Michael Eder

Partner

Dr. sc. nat., Dipl.-Chem.

Dr. Eder heads the firm’s chemistry practice group. Dr. Eder began his career in intellectual property in 1999 and joined df-mp in 2000. Since 2007, he is a partner in the firm. Dr. Eder is authorized to represent clients before the German Patent and Trademark Office, the German Federal Patent Court, the European Patent Office as well as the European Intellectual Property Office.

+ 49 89 210 296 0
michael.eder@df-mp.com
 

Dr. Eder heads the firm’s chemistry practice group. Dr. Eder began his career in intellectual property in 1999 and joined df-mp in 2000. Since 2007, he is a partner in the firm. Dr. Eder is authorized to represent clients before the German Patent and Trademark Office, the German Federal Patent Court, the European Patent Office as well as the European Intellectual Property Office.

practice areas.

Michael Eder advises German and foreign clients in all aspects of intellectual property, with an emphasis in the areas of pharmaceuticals, protein biochemistry, and industrial chemistry. His scientific background includes the fields of biophysical, organic und inorganic chemistry, as well as molecular biology. An important part of his practice relates to the drafting, prosecution and coordination of European and German patent applications, particularly in the area of pharmaceutical chemistry and protein biochemistry. Dr. Eder is furthermore responsible for numerous opposition proceedings before the EPO and has been involved in a number of national and multinational patent litigation cases. Another main focus of his work lies in rendering patent validity and infringement opinions in connection with freedom-to-operate und due diligence projects, as well as counselling clients in matters relating to supplementary protection certificates (SPCs) for pharmaceuticals in Europe.

  

Dr. Michael Eder speaks at the Georgetown University Law Center in Washington D.C.
Dr. Michael Eder speaks at the Georgetown University Law Center…

"Clinical Innovation: Fair and Effective Incentives for New Uses of…

admissions.

  • German Patent Attorney
  • European Patent Attorney
  • European Trademark Attorney
  • European Design Attorney

references and activities.

  • Author and co-author of numerous scientific publications in the field of protein biochemistry:Publications
  • Invited speaker at various international patent conferences und workshops
  • In 2013 Dr. Michael Eder was recommended by Global Law Experts as an expert for patent law in Germany.

curriculum vitae.

Since 2007
Since 2007

Partner at df-mp

Since 2003
Since 2003

European and German patent attorney at df-mp

2000-2002
2000-2002

Patent attorney candidate at df-mp

1999-2000
1999-2000

Entry into the field of intellectual property as a German patent attorney candidate in the law firm Frohwitter, Munich

1996-1999
1996-1999

Ph.D. studies at the Institute of Cell Biology (Swiss Federal Institute of Technology Zurich, Switzerland) / MPI for Biomedical Research in Heidelberg

1989-1995
1989-1995

Studies in Chemistry at the University of Konstanz, diploma thesis in the field of protein biochemistry

Representative cases.

  • Teva GmbH vs. OSI Pharmaceuticals & Pfizer Products Inc.:  represented Teva in a nullity action against the EP patent relating to Pfizer’s blockbuster anti-cancer drug Erlotinib / Tarceva®
  • Sandoz AG vs. Bristol-Myers Squibb (BMS) Holdings Ireland: representing Intervener (Sandoz) in EPO Opposition Proceedings in connection with Infringement / Arbitration Proceedings in Portugal
  • Teva Pharmaceutical Industries Ltd. (Israel) vs. Gilead Sciences, Inc. (USA): representing Teva in 5 Oppositions against Cobicistat base patent (EP 2 049 506 and 4 divisionals)
  • Teva Pharmaceutical Industries Ltd. (Israel) vs. Hoffmann La Roche (Switzerland): representing in Opposition against Erlotinib Polymorph Patent (EP 1 597 239 B1)
  • Lonza Ltd. (Switzerland) vs. Sangamo Biosciences, Inc. (USA): Representing Lonza  in EPO Opposition Proceedings against EP 2 281 050 B1

association memberships.

     

publications.

  • “Characterization of human and pig kidney long-chain-acyl-CoA dehydrogenases and their role in β-oxidation”, M. Eder, F. Kräutle, Y. Dong, P. Vock, V. Kieweg, J.J.-P. Kim, A. W. Strauss, and S. Ghisla; Eur J Biochem 245: 600-607, (1997).
  • “Substrate activation by acyl-CoA dehydrogenases: transition-state stabilization and pKs of involved functional groups”, P. Vock, S. Engst, M. Eder, S. Ghisla; Biochemistry 37: 1848-1860, (1998).
  • “Functional aspects of the X-ray structure of mitochondrial creatine kinase: a molecular physiology approach” U. Schlattner, M. Forstner, M. Eder, O. Stachowiak, K. Fritz-Wolf, T. Wallimann; Mol Cell Biochem 184: 125-140, (1998)
  • “Creatine kinase: an enzyme with a central role in cellular energy metabolism.” T. Wallimann, M. Dolder, U. Schlattner, M. Eder, T. Hornemann, T. Kraft, M. Stolz; MAGMA 6: 116-119, (1998).
  • “Some new aspects of creatine kinase (CK): compartmentation, structure, function and regulation for cellular and mitochondrial bioenergetics and physiology.” T. Wallimann, M. Dolder, U. Schlattner, M. Eder, T. Hornemann, E. O’Gorman, A. RĂĽck, D. Brdiczka; Biofactors 8 :229-234, (1998).
  • “Crystal structure of brain-type creatine kinase at 1.41Ă… resolution” M. Eder, U. Schlattner, A. Becker, T. Wallimann, W. Kabsch, K. Fritz-Wolf; Prot. Sci., Nov, 8 (11): 2258-69, (1999)
  • “Crystal structure of human ubiquitous mitochondrial creatine kinase”M. Eder, K. Fritz-Wolf, W. Kabsch, T. Wallimann, U. Schlattner; Proteins, May 15; 39(3): 216-25, (2000)
  • “A conserved negatively charged cluster in the active site of creatine kinase is critical for enzymatic activity” M. Eder, M. Stolz, T. Wallimann; U. Schlattner; J. Biol. Chem., Sep 1; 275(35): 27094-9, (2000)
  • “Divergent enzyme kinetics and structural properties of the two human mitochondrial creatine kinase isoenzymes” U. Schlattner, M. Eder, M., Dolder, Z.A. Khuchua, A.W. Strauss, T. Wallimann; Biol. Chem., Nov; 381(11): 1063-70, (2000)